DR3

DR3 Liste de produits

Attribut
Protein (7)Cell (1)
Bibliothèque de produits
En ligne (8)
Espèces
Cynomolgus (2)Human (5)Mouse (1)
Étiquette
Fc Tag (2)His Tag (3)- (1)Fc Tag & Avi Tag (1)His Tag & Avi Tag (1)
Marqueur
Unconjugated (5)- (1)Biotin-labeled (2)

Numéro de produit	Espèces	Système d'expression	Description du produit	Pré-commande/Commande
HOT DR3-H5253	Human	HEK293	Human DR3 Protein, Fc Tag, low endotoxin (MALS verified)	Ajouter au panier
HOT DR3-H82E3	Human	HEK293	Biotinylated Human DR3 / TNFRSF25 Protein, His,Avitag™ (MALS verified)	Ajouter au panier
HOT TN5-H52H3	Human	HEK293	Human DR3 / TNFRSF25 Protein, His Tag, low endotoxin (MALS verified)	Ajouter au panier
DR3-H82F3	Human	HEK293	Biotinylated Human DR3 / TNFRSF25 Protein, Fc,Avitag™ (MALS verified)	Ajouter au panier
SCJUR-STF178	Human	Jurkat	Human DR3 (TL1A receptor) (Luc) Jurkat Reporter Cell	Ajouter au panier
DR3-M52H3	Mouse	HEK293	Mouse DR3 / TNFRSF25 Protein, His Tag, low endotoxin (HPLC & SPR verified)	Ajouter au panier
DR3-C52H3	Cynomolgus	HEK293	Cynomolgus DR3 / TNFRSF25 Protein, His Tag, low endotoxin (SPR verified)	Ajouter au panier
TN5-C5257	Cynomolgus	HEK293	Cynomolgus DR3 / TNFRSF25 Protein, Fc Tag, low endotoxin	Ajouter au panier

Quantité totale8

DR3Contexte de la molécule

Tumor necrosis factor receptor superfamily member 25 (TNFRSF25) is also known as Apo-3, Death receptor 3 (DDR3 or DR3), Apoptosis-inducing receptor AIR, Apoptosis-mediating receptor TRAMP, Lymphocyte-associated receptor of death, Apo-3, which is a member of the TNF-receptor superfamily. TNFRSF25 is a homodimer protein, which can Interact strongly via the death domains with TNFRSF1 and TRADD to activate at least two distinct signaling cascades, apoptosis and NF-kappa-B signaling. TNFRSF25 is receptor for TNFSF12 / APO3L / TWEAK.

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Ontamalimab	SHP-647; PF-00547659; PF-547659	Phase 3 Clinical	Pfizer Inc	Ileitis; Colitis, Ulcerative; Crohn Disease	Details
Vedolizumab biosimilar (Polpharma Biologics)	PB-016	Phase 3 Clinical	Polpharma Biologics Sa	Pouchitis; Colitis, Ulcerative; Crohn Disease	Details

Informations sur les médicaments commercialisés

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Plus ancien nom de marque	Pays d'approbation le plus ancien	Indication la plus ancienne	Société d'approbation la plus ancienne	Date d'approbation la plus ancienne	Indication	Essai clinique
Vedolizumab	MLN-0002; LPD-02; MLN-002; MLN-02; LDP-02	Approved	Millennium Pharmaceuticals Inc	安吉优, Entyvio	United States	Colitis, Ulcerative; Crohn Disease	Takeda Pharmaceuticals USA Inc	2014-05-20	Celiac Disease; Carcinoma, Non-Small-Cell Lung; Melanoma; Crohn Disease; Gastritis; Urogenital Neoplasms; Colitis, Ulcerative; Cholangitis, Sclerosing; Pediatric ulcerative colitis; Solid tumours; Colitis; Pouchitis; Neoplasms; Pediatric Crohn's disease; Inflammatory Bowel Diseases; HIV Infections; Hematopoietic stem cell transplantation (HSCT)	Details